Category: Europe

December 7, 2021 Off

Pure Tech kicks off study for its neuro conditions treatment candidate

By Dino Mustafić

PureTech Health has kicked off a clinical study of LYT-300 (oral allopregnanolone), its wholly-owned therapeutic candidate for the potential treatment of neurological and neuropsychological conditions, including depression, anxiety, sleep disorders, fragile X tremor-associated syndrome, essential tremor and epileptic disorders, among others. LYT-300 is the third clinical-stage, wholly-owned candidate from PureTech’s pipeline. 

LEO Pharma shared new Adtralza results
September 30, 2021 Off

LEO Pharma shared new Adtralza results

By Dino Mustafić

LEO Pharma shared results showing that after two years of continuous treatment with Adtralza, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life
September 29, 2021 Off

Novartis data show achieving complete control of chronic spontaneous urticaria (CSU) improves overall quality of life

By Dino Mustafić

Novartis’ dana from new analysis from a Phase IIb study has showed the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients, as complete control of symptoms brings enormous benefit to people with CSU and is associated with improvements in key HRQoL measures such as overall quality of life, sleep interference, activity interference and work impairment.

Santhera nets CHF 45 Million in funding
September 20, 2021 Off

Santhera nets CHF 45 Million in funding

By Dino Mustafić

Santhera Pharmaceuticals has announced a cahs boost with an oversubscribed equity financing of CHF 20 million, a placement of private convertible bonds of CHF 15 million and upsizing of an existing financing arrangement of up to CHF 10 million.